Ken Horne has over 20 years of experience in the life science industry as an executive, entrepreneur, and investor. He joined Advantary LLC as a Partner in 2019. In addition, he is currently President and COO of Teon Therapeutics, which he joined in 2019. Previously, Mr. Horne was CEO of Symic Bio starting in 2014. Under his leadership, Symic raised over $90M in funding and advanced two first-in-category drugs into phase 2 studies. Both assets have been partnered. Before Symic, Mr. Horne was a founding member of TauTona Group, an early-stage life science venture capital fund. At TauTona, Mr. Horne founded Aline Aesthetics, a novel biomaterial company, where he led the company as General Manager until its acquisition by Allergan (AGN) in 2014. He also served as Vice President of Business Development for TauTona portfolio companies, which included acquisitions by LifeCell and Novadaq (NVDQ).
Earlier in his career, Ken worked extensively in cardiovascular research as part of The Foundry and contributed to the development of Evalve’s MitraClip (acquired by Abbott Vascular). He has over 30 issued patents.
Ken serves on the Board of Directors of Teon Therapeutics, Symic Bio, AfaSci, and is a Partner at Advantary. He has a B.S. and M.S. degree from Stanford University in mechanical engineering and is a Kauffman Fellow.
Biz Dev, Capital Raising, Contract Negotiation, Debt, Due Diligence, Equity, Finance, IP/Patent Strategy, Licensing, Management, and Operations
Hong Kong and San Francisco
CEO: Chief Executive Officer and COO: Chief Operating Officer
Consulting, Digital Health, Finance/Banking, Healthcare, Nonprofit, and Venture